PARP1 inhibitors are used in cancer therapies in the setting of BRCA1 (breast cancer type 1 susceptibility protein) or BRCA2 (breast cancer type 2 susceptibility protein) loss (olaparib and rucaparib approved by FDA in patients with HR dysfunction). Here, BRCA2 is linked to cancer.